Skip to main content

Peer Review reports

From: Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study

Original Submission
5 Sep 2023 Submitted Original manuscript
2 Oct 2023 Reviewed Reviewer Report
7 Oct 2023 Reviewed Reviewer Report
9 Oct 2023 Reviewed Reviewer Report
14 Oct 2023 Reviewed Reviewer Report
26 Oct 2023 Author responded Author comments - Qi Xiong
Resubmission - Version 2
26 Oct 2023 Submitted Manuscript version 2
27 Oct 2023 Author responded Author comments - Qi Xiong
Resubmission - Version 3
27 Oct 2023 Submitted Manuscript version 3
10 Nov 2023 Reviewed Reviewer Report
14 Nov 2023 Reviewed Reviewer Report
19 Nov 2023 Reviewed Reviewer Report
4 Dec 2023 Author responded Author comments - Qi Xiong
Resubmission - Version 4
4 Dec 2023 Submitted Manuscript version 4
8 Dec 2023 Author responded Author comments - Qi Xiong
Resubmission - Version 5
8 Dec 2023 Submitted Manuscript version 5
27 Dec 2023 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
3 Jan 2024 Editorially accepted
17 Jan 2024 Article published 10.1186/s12885-024-11833-6

You can find further information about peer review here.

Back to article page